Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICARDIS HCT vs CIMZIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.
Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.
Treatment of hypertension, alone or in combination with other antihypertensive agents
Crohn's disease (FDA approved for adults with moderately to severely active disease),Rheumatoid arthritis (FDA approved for adults with moderately to severely active disease),Psoriatic arthritis (FDA approved for adults),Ankylosing spondylitis (FDA approved for adults),Plaque psoriasis (off-label use),Axial spondyloarthritis (off-label use)
One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.
400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.
Telmisartan: terminal half-life ≈24 hours, allowing once-daily dosing. Hydrochlorothiazide: 6-15 hours (mean 10 hours).
14 days (range 11-17 days) following subcutaneous administration; supports every 2-week or monthly dosing intervals.
Telmisartan is primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT1A8; it is not metabolized by CYP450 enzymes. Hydrochlorothiazide is not extensively metabolized; it is eliminated unchanged in the urine.
Certolizumab pegol is a monoclonal antibody fragment that is not metabolized by cytochrome P450 enzymes. It is degraded by proteolysis into small peptides and amino acids.
Primarily biliary excretion (≈60%) and renal excretion (≈40%) as unchanged drug. Telmisartan: renal <1%, fecal >97%. Hydrochlorothiazide: renal >95% unchanged.
Primarily eliminated via reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Clinical pharmacokinetic studies show no dose adjustment needed in renal impairment.
Telmisartan: >99.5% bound primarily to albumin and α1-acid glycoprotein. Hydrochlorothiazide: 40-68% bound to albumin.
Not applicable (monoclonal antibody); typically does not bind to serum proteins other than target antigen.
Telmisartan: 500 L (≈7 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: 0.8-1.2 L/kg, confined to extracellular fluid.
~5.7 L (approx. 0.08 L/kg for a 70 kg patient), indicating predominant distribution in vascular space with limited extravascular penetration.
Telmisartan: absolute oral bioavailability ≈42-58% (dose-dependent). Hydrochlorothiazide: oral bioavailability ≈65-75%.
Subcutaneous: ~80% (range 63-92%) relative to intravenous administration.
Contraindicated if GFR <30 m L/min. No adjustment needed for GFR 30-89 m L/min. Monitor renal function.
No dose adjustment required for renal impairment. Not studied in severe renal impairment.
Contraindicated in severe hepatic impairment (Child-Pugh C). Caution and possible dose reduction in mild-to-moderate impairment; maximum 40 mg/12.5 mg daily.
No dose adjustment required for hepatic impairment. Not studied in severe hepatic impairment (Child-Pugh C).
Safety and efficacy not established in pediatric patients (<18 years).
Not approved for use in pediatric patients. Safety and efficacy not established.
No initial dose adjustment required; monitor blood pressure and renal function, especially with concurrent diuretic therapy.
No specific dose adjustment in elderly; use with caution due to increased infection risk.
None
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to opportunistic pathogens. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
Avoid use in pregnancy; can cause fetal harm when administered to a pregnant woman (discontinue as soon as possible when pregnancy is detected),May cause symptomatic hypotension in patients with volume or salt depletion,Monitor renal function; may cause acute renal failure, especially in patients with renal artery stenosis,Monitor serum electrolytes; risk of electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia) due to hydrochlorothiazide,May exacerbate or activate systemic lupus erythematosus,May cause acute angle-closure glaucoma (due to hydrochlorothiazide),May cause hypersensitivity reactions, including anaphylaxis and angioedema (telmisartan),Use with caution in patients with hepatic impairment (telmisartan),Use with caution in patients with diabetes or impaired renal function; may increase risk of renal impairment when used with NSAIDs or COX-2 inhibitors,Monitor for hyperuricemia and gout,May cause photosensitivity reactions
Serious infections (reactivation of TB, fungal infections, bacterial sepsis), malignancies (including lymphoma and non-melanoma skin cancer), hepatitis B virus reactivation, demyelinating disease (e.g., multiple sclerosis), congestive heart failure (new onset or exacerbation), hematologic abnormalities (pancytopenia, aplastic anemia), hypersensitivity reactions (including anaphylaxis), and lupus-like syndrome.
Hypersensitivity to telmisartan, hydrochlorothiazide, or any component of the formulation,Anuria (due to hydrochlorothiazide),Concomitant use with aliskiren in patients with diabetes mellitus,Severe renal impairment (Cr Cl <30 m L/min),Severe hepatic impairment
Active serious infection, including sepsis, tuberculosis, and opportunistic infections. Known hypersensitivity to certolizumab pegol or any of its components.
Avoid high-potassium foods (bananas, oranges, tomatoes, spinach, salt substitutes) due to telmisartan's potassium-sparing effect. Hydrochlorothiazide may cause hypomagnesemia and hypokalemia; ensure adequate intake of magnesium-rich foods (nuts, whole grains) and potassium-rich foods (if not contraindicated). Avoid excessive alcohol intake which can increase hypotensive effect.
No known food interactions. Take with or without food. No dietary restrictions required.
First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligohydramnios, skull ossification defects, hypotension, and anuria. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. Due to minimal placental transfer (low Fc receptor binding), first trimester exposure shows no increased risk of major birth defects. Limited data in second and third trimesters; theoretical risk of immunosuppression in fetus. No known teratogenic effect in animal studies.
Telmisartan is excreted in human milk in very low concentrations; M/P ratio unknown for telmisartan. Hydrochlorothiazide is excreted in breast milk; M/P ratio approximately 1.6. Avoid breastfeeding due to potential for adverse effects on the infant, including electrolyte disturbances and hypotension.
Minimal transfer into breast milk due to high molecular weight and PEGylation. M/P ratio not established. Consider benefits of breastfeeding vs risk of infant exposure. American Academy of Pediatrics considers compatible with breastfeeding.
No dose adjustment data specific to pregnancy for Micardis HCT. Due to risk of fetal harm, use is contraindicated in pregnancy; discontinue as soon as pregnancy is detected. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may theoretically require dose adjustment, but no established guidelines.
No standard dose adjustment required. Pharmacokinetics not significantly altered in pregnancy due to low placental transfer. Continue standard dosing; delay live vaccines in infants for 6 months after last maternal dose.
MICARDIS HCT (telmisartan/hydrochlorothiazide) is a fixed-dose combination for hypertension not controlled on monotherapy. Monitor renal function, electrolytes (especially potassium and sodium), and volume status. Avoid in severe renal impairment (Cr Cl <30 m L/min) and anuria. Assess for hypotension, particularly in volume-depleted patients. Use with caution in hepatic impairment, diabetes, and history of angioedema. May cause fetal harm in pregnancy; discontinue as soon as possible. Telmisartan is not dialyzable.
CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. It lacks an Fc region, which reduces placental transfer, making it a preferred biologic for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease during pregnancy. Administer subcutaneously. Monitor for infections, including TB reactivation. Do not administer live vaccines concurrently. Injection site reactions are common; pre-medication with antihistamines may reduce them.
Take exactly as prescribed; do not skip doses or take double doses.,Notify your doctor immediately if you become pregnant or plan to become pregnant.,Avoid alcohol, NSAIDs, and salt substitutes containing potassium.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, confusion, or decreased urination.,This medication may increase blood sugar; monitor if you have diabetes.
Do not receive live vaccines (e.g., MMR, nasal flu, yellow fever) while on CIMZIA. Discuss vaccination schedule with your doctor.,Report any signs of infection (fever, cough, painful urination) or allergic reactions (rash, difficulty breathing) immediately.,Store CIMZIA in the refrigerator at 2°C to 8°C. Do not freeze. Protect from light. Allow to reach room temperature before injection.,Use proper injection technique; rotate injection sites (abdomen, thigh). Discard unused portions in a sharps container.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. CIMZIA has low placental transfer and may be used during pregnancy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICARDIS HCT vs CIMZIA, answered by our medical review team.
MICARDIS HCT is a Antihypertensive Combination (ARB + Thiazide Diuretic) that works by Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.. CIMZIA is a TNF-alpha Inhibitor that works by Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICARDIS HCT and CIMZIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICARDIS HCT is: One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.. The standard adult dose of CIMZIA is: 400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICARDIS HCT and CIMZIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICARDIS HCT is classified as Category C. First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligoh. CIMZIA is classified as Category C. CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. Due to minimal placental transfer (low Fc receptor binding), first trimester exposure shows no incr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.